You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameDihydroetorphine
Accession NumberDB01450
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQQX8S479YV
CAS number14357-76-7
WeightAverage: 413.5497
Monoisotopic: 413.256608613
Chemical FormulaC25H35NO4
InChI KeyBRTSNYPDACNMIP-FAWZKKEFSA-N
InChI
InChI=1S/C25H35NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,17-18,21,27-28H,5,8-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1
IUPAC Name
(1S,2R,6S,14R,15R,16R)-16-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-3-methyl-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydroetorphine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydroetorphine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dihydroetorphine.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydroetorphine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydroetorphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydroetorphine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dihydroetorphine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydroetorphine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Asenapine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydroetorphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydroetorphine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azaperone.Vet Approved
AzelastineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydroetorphine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydroetorphine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydroetorphine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydroetorphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydroetorphine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Dihydroetorphine.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydroetorphine.Approved, Investigational
BuprenorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroetorphine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydroetorphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydroetorphine.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Dihydroetorphine.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydroetorphine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydroetorphine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydroetorphine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydroetorphine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydroetorphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydroetorphine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydroetorphine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydroetorphine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydroetorphine.Approved, Vet Approved
CitalopramDihydroetorphine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydroetorphine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydroetorphine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydroetorphine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydroetorphine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydroetorphine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydroetorphine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydroetorphine.Approved
DapoxetineDihydroetorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydroetorphine.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydroetorphine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.Approved
DesvenlafaxineDihydroetorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydroetorphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydroetorphine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydroetorphine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydroetorphine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydroetorphine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydroetorphine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Dihydroetorphine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydrocodeine.Approved, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydroetorphine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydroetorphine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Drotebanol.Experimental, Illicit
DuloxetineDihydroetorphine may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efonidipine.Approved
EluxadolineDihydroetorphine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydroetorphine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Eplerenone.Approved
EscitalopramDihydroetorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydroetorphine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydroetorphine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etacrynic acid.Approved
EthanolDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydroetorphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydroetorphine.Approved
EtoperidoneDihydroetorphine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroetorphine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydroetorphine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flunitrazepam.Approved, Illicit
FluoxetineDihydroetorphine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydroetorphine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydroetorphine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydroetorphine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroetorphine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydroetorphine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydroetorphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydroetorphine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydroetorphine.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydroetorphine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydroetorphine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydroetorphine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydroetorphine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydroetorphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydroetorphine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydroetorphine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydroetorphine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dihydroetorphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydroetorphine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Imipramine.Approved
IndalpineDihydroetorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Indapamide.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydroetorphine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydroetorphine.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydroetorphine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketobemidone.Approved
KW-3902The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydroetorphine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydroetorphine.Approved
LevomilnacipranDihydroetorphine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydroetorphine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydroetorphine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydroetorphine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydroetorphine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydroetorphine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydroetorphine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydroetorphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydroetorphine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Dihydroetorphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Dihydroetorphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydroetorphine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydroetorphine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydroetorphine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydroetorphine.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydroetorphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydroetorphine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydroetorphine.Approved
MethotrimeprazineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydroetorphine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Dihydroetorphine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydroetorphine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydroetorphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone.Approved
MetyrosineDihydroetorphine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine.Approved, Illicit
MilnacipranDihydroetorphine may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved, Investigational
MirtazapineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dihydroetorphine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydroetorphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dihydroetorphine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved, Investigational
NalbuphineNalbuphine may decrease the analgesic activities of Dihydroetorphine.Approved
NaltrexoneThe therapeutic efficacy of Dihydroetorphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneDihydroetorphine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dihydroetorphine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydroetorphine.Approved
OpiumThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Opium.Approved, Illicit
OrphenadrineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydroetorphine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydroetorphine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydroetorphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydroetorphine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydroetorphine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydroetorphine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydroetorphine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydroetorphine.Approved
ParaldehydeDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineDihydroetorphine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.Approved
PentazocinePentazocine may decrease the analgesic activities of Dihydroetorphine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydroetorphine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydroetorphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydroetorphine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydroetorphine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydroetorphine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Dihydroetorphine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydroetorphine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydroetorphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydroetorphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDihydroetorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydroetorphine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydroetorphine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydroetorphine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydroetorphine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydroetorphine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydroetorphine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydroetorphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydroetorphine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dihydroetorphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydroetorphine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydroetorphine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dihydroetorphine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydroetorphine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydroetorphine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ramelteon.Approved, Investigational
RamosetronDihydroetorphine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydroetorphine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydroetorphine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydroetorphine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dihydroetorphine.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Romifidine.Vet Approved
RopiniroleDihydroetorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroetorphine.Approved
RotigotineDihydroetorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydroetorphine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydroetorphine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydroetorphine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Sertindole.Approved, Withdrawn
SertralineDihydroetorphine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydroetorphine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydroetorphine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydroetorphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydroetorphine.Approved
SuvorexantDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydroetorphine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrodotoxin.Investigational
ThalidomideDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydroetorphine.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydroetorphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydroetorphine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dihydroetorphine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiapride.Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydroetorphine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydroetorphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroetorphine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydroetorphine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroetorphine.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydroetorphine.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydroetorphine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydroetorphine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydroetorphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydroetorphine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydroetorphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydroetorphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydroetorphine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydroetorphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydroetorphine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydroetorphine.Approved
VenlafaxineDihydroetorphine may increase the serotonergic activities of Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydroetorphine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ziconotide.Approved
ZimelidineDihydroetorphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydroetorphine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zolazepam.Vet Approved
ZolpidemDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydroetorphine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9829
Blood Brain Barrier+0.9712
Caco-2 permeable+0.7053
P-glycoprotein substrateSubstrate0.9173
P-glycoprotein inhibitor IInhibitor0.7031
P-glycoprotein inhibitor IINon-inhibitor0.8397
Renal organic cation transporterNon-inhibitor0.6108
CYP450 2C9 substrateNon-substrate0.8678
CYP450 2D6 substrateSubstrate0.7836
CYP450 3A4 substrateSubstrate0.8022
CYP450 1A2 substrateNon-inhibitor0.9409
CYP450 2C9 inhibitorNon-inhibitor0.8912
CYP450 2D6 inhibitorNon-inhibitor0.6514
CYP450 2C19 inhibitorNon-inhibitor0.8578
CYP450 3A4 inhibitorNon-inhibitor0.8133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9418
Ames testNon AMES toxic0.7704
CarcinogenicityNon-carcinogens0.9335
BiodegradationNot ready biodegradable0.9958
Rat acute toxicity3.4494 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8552
hERG inhibition (predictor II)Non-inhibitor0.6577
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.114 mg/mLALOGPS
logP2.98ALOGPS
logP2.66ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.5ChemAxon
pKa (Strongest Basic)11.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity115.55 m3·mol-1ChemAxon
Polarizability46.49 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Azaspirodecane
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23